Skip to main content

Dealing with EIRs

Recently, I have come across quite a few VC (and in some cases even PE) firms in India taking on board Entrepreneurs in Residence (EIRs). Simultaneously, I have begun to hear entrepreneurs pitching to these firms express concerns on the potential conflicts of interest in the EIRs sitting through their presentations and doing diligence on their companies.

What exactly in an EIR? Here is an extract from the Wikipedia entry:
The role of an EIR varies from fund to fund (and entrepreneur to entrepreneur), but typically it involves an individual that wants to start a company. The entrepreneur may enter the position with an idea at various stages of development. Sometimes an entrepreneur has already spent a great deal of time on the idea and is leveraging the EIR position for office space and mindshare with VCs.

Another EIR role is to act as a “partner” and help VCs evaluate potential deals where the entrepreneur has a particular expertise. An EIR might also spend some time with an existing portfolio company to provide his or her functional expertise. In this scenario, the EIR will sometimes enter the company as a full time executive (typically CEO or some “C” level role) if the company and the executive feel there is a good fit.

The Funded has an (anonymous) post which expands on the "inherent CONFLICT OF INTEREST posed by EIRs sitting with the VCs who in turn sit at the gathering point of new ideas from trusting entrepreneurs".
I can't imagine that it's ok for a doctor to refer his patients to surgical clinics owned and funded by himself. There could be all kinds of arguments as to how that would be practical, but it still appears inappropriate and fraught with ethical compromises. Which is why the American Medical Association rejects this concept of self-referral. The EIR concept is even more problematic, even with full disclosure, since there is no easy ethical resolution for the inherent conflicts of interest.

For those VCs who would shy from any hint of impropriety, it would be a simple matter to set a policy that no EIR would form a startup in an area where someone has pitched an idea in the last 12 months. Alternatively, don't receive pitches where an EIR wants to start something.

But I’m sure we’ll hear a thousand reasons why such guidelines would not work ... which then leads to a simple solution: Do away with EIRs entirely.

As EIR programs have been around for quite a while at US VC firms (and apparently becoming more popular), VCs importing the concept to India are unlikely to abandon them. However, in the interest of a healthy ecosystem, here's hoping that VCs actively inform entrepreneurs (who approach them for funding) on the role of their EIRs and give them an early option to "opt out" of disclosing more information about their companies/plans.

Arun Natarajan is the Founder & CEO of Venture Intelligence, the leading provider of information and networking services to the private equity and venture capital ecosystem in India. View free samples of Venture Intelligence newsletters and reports.

Popular posts from this blog

EY Tops League Table for Transaction Advisors to M&A deals in 24

Moelis & Company & PwC claim the No.2 & No.3 slots Ernst & Young  (EY) topped the Venture Intelligence League Table for Transaction Advisor to M&A Deals   during 2024, advising 34 deals worth $4.1 Billion. Moelis & Company stood second advising 2 deals worth $3.9 billion. PwC followed with 18 deals worth $3.3 billion. Citi ($2.5 billion across 1 deal) and Advay Capital ($2.3 billion across 1 deal) completed the top five. Among the largest M&A deals in 2024, Citi  advised $2.5 Billion acquisition of the Indian business of American Tower Corporation by Brookfield , Advay Capital and Moelis & Company advised the $2.3 Billion acquisition of Care Hospitals by Aster DM Healthcare . Jefferies & Co., JP Morgan and Moelis & Company advised the $1.6 Billion acquisition of Bharat Serums & Vaccines by Mankind Pharma.  Among the other notable M&A deals in Q4 2024, EY advised the $685 million acquisition of ITD Cementation ...

Morgan Stanley tops League Table for Transaction Advisors to M&A deals in 2020

Morgan Stanley , which advised the $10.1 Billion strategic investment by Facebook and Google into Reliance Industries' telecom arm Jio platforms (among other Private Equity investments in the company), topped the Venture Intelligence League Table for Transaction Advisor to M&A Deals for 2020. Ambit Corporate Finance - which advised 3 deals worth $4.0 Billion, including Brookfield's $3.7 Billion acquisition of Reliance Tower Infrastructure Trust -  took the second spot. JM Financial ($3.7 Billion across 5 deals), Metta Capital ($3.4 Billion across 3 deals) and ICICI Securities ($3.4 Billion across 2 deals) - all of whom (along with Citi) are advisors to the $3.4 Billion acquisition of Future Group's retail related ventures by Reliance Retail, announced in August - completed the top five. The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on the value of PE and M&A tra...

Everything you wanted to know (and some things you didn't care to know) about ChrysCapital's Ashish Dhawan

New Delhi-based private equity fund ChrysCapital is vastly different from its former avatar, Chrysalis Capital. While Chrysalis began life (in Mumbai) as an venture capital firm focussed on start-up investments, today's ChrysCapital is best know for its late-stage investments (often in already public companies). The fascinating part of this transformation is that one of the fund's original partners - Senior Managing Director Ashish Dhawan - has been firmly in the driver's seat throughout the process. It's a story that needed to be told. As a cover story. Kudos to Business Today for telling it first. Thankfully, unlike the glowing profiles that BT is famous for - including the one featuring infamous stock brocker Harshad Mehta with his Lexus on the cover - this one has a lot of facts. Some well known. And others less so. That ChrysCapital's first fund would have been a disaster but for the pioneering investment in Raman Roy founded BPO firm Spectramind i...

APEX VC Awards: Chiratae Ventures, Blume Ventures, Elevation Capital, Stride Ventures & Alteria Capital judged best funds of 2021

Press Release Elevation Capital , Chiratae Ventures , Blume Ventures , Stride Ventures and Alteria Capital were voted the top Venture Capital investors in India during 2021. The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. "VCs exist because Entrepreneurs exist and disrupt the ecosystem by creating new businesses. We are very excited to be part of the secular trend of tech disruption that would power India’s journey towards $ 10 Trillion economy over the next decade," said  T C Meenakshi Sundaram, Founder & Vice Chairman, Chiratae Ventures , winner of " VC Fund raise of the Year " award.  " We wish to thank all our entrepreneurs who have chosen to take funding from Chiratae Ventures and investors who have backed us with funds over the past 15 years in this journey.  Congratulations to the entire Chiratae Ventures team and ...

VC Interview: Shailendra Singh of Sequoia Capital India

In a recent interview to Venture Intelligence, Shailendra Singh discussed some of the firm’s newer investments in the early stage segment including in the online payments space, the progress at a few existing portfolio companies and the active role the firm is playing in helping its portfolio companies scale and succeed in India and globally. Prior to joining the firm in 2006, Singh was a strategy consultant at Bain & Company in New York and before that, an entrepreneur in the digital media industry. Venture Intelligence: How does Sequoia go about identifying potential early stage investments in India? Is there anything different you are doing today than, say, a couple of years back? Shailendra Singh: There is a lot more focus on technology investing and early stage investing. In general, as you might remember a few years ago, we were doing primarily growth investing but in the past 18-odd months, we have had a very strong focus on early stage and that’s continuing. In terms...